» Articles » PMID: 8666818

Binding of Model Soluble Immune Complexes to Modified C-reactive Protein

Overview
Journal J Immunol
Date 1996 Jun 1
PMID 8666818
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

We have identified a binding interaction between a modified form of C-reactive protein (mCRP) and model immune complexes. We have characterized these interactions in terms of their relative affinity, specificity, pH dependence, and recognition site on mCRP. First, binding isotherms were generated for the reaction of immobilized mCRP with heat-aggregated IgG (HAG) which gave an estimate for the value of the dissociation constant, Kd, of 1.6 nM. Second, competitive binding assays were performed using immobilized HAG to determine the relative affinity (IC50) for the interaction between HAG or monomeric IgG and mCRP in the fluid phase. While the binding of HAG to mCRP occurred with high affinity (IC50=0.72 nM), the binding of monomeric IgG to mCRP occurred with >2000-fold lower affinity (IC50>1.66 muM). Third, immune complex binding to immobilized mCRP was studied using defined ratios of horseradish peroxidase and rabbit anti-peroxidase Ab. The binding of these complexes to mCRP was strongly pH dependent, with a maximum at pH 5.5. At this optimal pH, preformed peroxidase-antiperoxidase immune complexes (approximately 2:3 Ab:Ag molar ratio) were shown to bind immobilized mCRP with a Kd of 111 nM. Fourth, using mCRP-specific mAbs, HAG and peroxidase- antiperoxidase binding sites were localized to CRP sequences to 130 to 138 and 200 to 206. Since inflammatory processes often cause microenvironments to become acidic, and since mCRP selectively binds immune complexes at acidic pH, we propose that mCRP mediates the specific binding of immune complexes in vivo and potentiates effector reactions for immune complex removal.

Citing Articles

C-reactive protein: structure, function, regulation, and role in clinical diseases.

Zhou H, Tang Y, Xu T, Cheng B Front Immunol. 2024; 15:1425168.

PMID: 38947332 PMC: 11211361. DOI: 10.3389/fimmu.2024.1425168.


C-reactive protein lowers the serum level of IL-17, but not TNF-α, and decreases the incidence of collagen-induced arthritis in mice.

Singh S, Prislovsky A, Ngwa D, Munkhsaikhan U, Abidi A, Brand D Front Immunol. 2024; 15:1385085.

PMID: 38650931 PMC: 11033386. DOI: 10.3389/fimmu.2024.1385085.


Associations of C-reactive protein isoforms with systemic lupus erythematosus phenotypes and disease activity.

Karlsson J, Wettero J, Weiner M, Ronnelid J, Fernandez-Botran R, Sjowall C Arthritis Res Ther. 2022; 24(1):139.

PMID: 35690780 PMC: 9188243. DOI: 10.1186/s13075-022-02831-9.


The Complex Role of C-Reactive Protein in Systemic Lupus Erythematosus.

Enocsson H, Karlsson J, Li H, Wu Y, Kushner I, Wettero J J Clin Med. 2021; 10(24).

PMID: 34945133 PMC: 8708507. DOI: 10.3390/jcm10245837.


C-Reactive Protein and Cancer: Interpreting the Differential Bioactivities of Its Pentameric and Monomeric, Modified Isoforms.

Potempa L, Rajab I, Olson M, Hart P Front Immunol. 2021; 12:744129.

PMID: 34552600 PMC: 8450391. DOI: 10.3389/fimmu.2021.744129.